Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201786 | 0.83 | CRHR1 (0.60) | CRHR1BRD4 | |
| SCHEMBL6203614 | 0.83 | CRHR1 (0.70) | CRHR1BRD4 | |
| SCHEMBL5415730 | 0.82 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL7477682 | 0.81 | CRHR1 (0.57) | CRHR1BRD4 | |
| SCHEMBL6201263 | 0.79 | CRHR1 (0.62) | CRHR1BRD4TLR8TLR7 | |
| SCHEMBL7482495 | 0.79 | CRHR1 (0.41) | CRHR1ABL1BRD4KCNH2RUNX1 | |
| SCHEMBL7477918 | 0.77 | CRHR1 (0.70) | CRHR1 | |
| SCHEMBL7480917 | 0.76 | CRHR1 (0.51) | CRHR1ABL1ADORA3RUNX1 | |
| SCHEMBL7476681 | 0.76 | CRHR1 (0.58) | CRHR1ADORA3BRD4 | |
| SCHEMBL7473622 | 0.76 | CRHR1 (0.58) | CRHR1BRD4TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255740-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060806-A2 | SUBSTITUTED ARYLPYRAZINES | NEUROGEN CORPORATION (US) | 2001-08-23 | — | — | WO | disclosed |